National Institutes of Health (NIH) Funding: FY1996-
FY2023
March 8, 2023
Kavya Sekar
This report details the National Institutes of Health (NIH) budget and appropriations process with
Analyst in Health Policy
a focus on FY2022 and FY2023. NIH is the primary federal agency charged with conducting and

supporting medical, health, and behavioral research. It is made up of 27 Institutes and Centers
and the Office of the Director (OD). More than 84% of the NIH budget funds extramural research

through grants, contracts, and other awards to universities and other research institutions. About
10% of NIH funding goes to intramural researchers at NIH-operated facilities. Almost all of NIH’s funding is provided in the
annual Departments of Labor, Health and Human Services, and Education, and Related Agencies (LHHS) Appropriations
Act. NIH also receives smaller amounts of funding from the Interior, Environment, and Related Agencies (INT)
Appropriations Act and a mandatory budget authority for type 1 diabetes research.
The FY2023 NIH program level of $49.183 billion represents a $3 billion increase (+6.5%) relative to FY2022 enacted
program level. The FY2023 enacted total for NIH is also $13.324 billion (-21.3%) less than the FY2023 budget request
program level. (The budget request included a $12 billion pandemic preparedness mandatory appropriations proposal that
was not adopted by Congress.) In FY2023, all Institute and Center (IC) accounts receive an increase relative to FY2022
funding levels (see Table A-1). In addition, the NIH FY2023 program level in this CRS report includes $1.5 billion for the
Advanced Research Projects Agency for Health (ARPA-H), a new agency within NIH that was first funded in FY2022.
ARPA-H received FY2023 appropriations in a separate account under the HHS Office of the Secretary. ARPA-H was
formally authorized as a part of the PREVENT Pandemics Act (P.L. 117-328, Division FF, Title II), which placed the agency
within NIH by statute.
NIH has seen periods of high and low funding growth during the period covered by this report, as illustrated in Figure 1.
Between FY1996 and FY1998, funding for NIH grew from $11.928 billion to $13.675 billion (nominal dollars). Over the
next five years, Congress and the President doubled the NIH budget to $27.167 billion in FY2003. In each of FY1999
through FY2003, NIH received annual funding increases of 14% to 16%. From FY2003 to FY2015, NIH funding increased
more gradually in nominal dollars. In some years (FY2006, FY2011, and FY2013), agency funding decreased in nominal
dollars. From FY2016 through FY2023, NIH has seen funding increases each year.
When looking at NIH funding adjusted for inflation (in projected constant FY2022 dollars using the Biomedical Research
and Development Price Index; BRDPI), the purchasing power of NIH funding initially peaked in FY2003—the last year of
the five-year doubling period—and then declined fairly steadily for more than a decade until funding increases were provided
in each of FY2016 through FY2023. In inflation-adjusted dollars, the FY2023 program level is 1.2% greater than the FY2003
program level at the end of the doubling period. However, the inflation-adjusted FY2023 program level includes funding for
the new ARPA-H, and therefore is not directly comparable to the FY2003 level. Excluding ARPA-H, the inflation-adjusted
FY2023 program level is -1.9% less than the FY2003 level.
This CRS report details NIH budget and appropriations for FY2022 and FY2023, and provides an overview of funding trends
in regular appropriations to the agency from FY1996 to FY2023. Coronavirus supplemental funding for NIH is discussed in
Appendix B of the report but is generally not included in the budgetary figures elsewhere in the report. Appendix A includes
funding tables by account and program-specific funding levels for FY2023. Appendix C provides a list of acronyms and
abbreviations used in the report.

Congressional Research Service

link to page 20 National Institutes of Health (NIH) Funding: FY1996-FY2023

NIH Funding: FY1996-FY2023
This report details the National Institutes of Health (NIH) budget and appropriations process with
a focus on FY2022 and FY2023. Almost all of NIH’s funding is provided in the annual
Departments of Labor, Health and Human Services, and Education, and Related Agencies
(LHHS) Appropriations Act. NIH also receives smaller amounts of funding from the Interior,
Environment, and Related Agencies (INT) Appropriations Act and a mandatory budget authority
for type 1 diabetes research.1
NIH is the primary federal agency for medical, health, and behavioral research. It is the largest of
the agencies that make up the Public Health Service (PHS) within the Department of Health and
Human Services (HHS).2 NIH consists of the Office of the Director (OD) and 27 Institutes and
Centers (ICs) that focus on aspects of health, human development, and biomedical science. Of
these, 24 ICs and OD support research programs. The OD sets overall policy for NIH and
coordinates the programs and activities of all NIH components, particularly in areas of research
that involve multiple institutes. Through the annual appropriations process, Congress provides
funding to the 24 research ICs, OD, and a Buildings and Facilities account. Three support centers
are funded through transfers from other accounts.
In addition, FY2022 appropriations established a new entity that has been placed within NIH: the
Advanced Research Projects Agency for Health (ARPA-H), as discussed further in this report.
NIH activities cover a wide range of basic,
Supplemental Funding for NIH
clinical, and translational research, focused on
In FY2021 and prior years, NIH received supplemental
particular diseases, areas of human health and
appropriations provided as an emergency requirement.
development, or more fundamental aspects of
Given that this report examines trends in regular
biology and behavior. Its mission also includes
annual appropriations to NIH enacted by Congress and
the President for the normal operations of the agency,
research training and health information
amounts provided to NIH pursuant to an emergency
collection and dissemination.3 More than 84%
requirement are generally excluded from this report. In
of the NIH budget funds extramural research
some years, supplemental funding to NIH was
(i.e., external) through grants, contracts, and
substantial, such as the over $10 bil ion in
other awards. This funding supports research
appropriations provided in the American Recovery and
Reinvestment Act of 2009 (ARRA; P.L. 111-5), which
performed by more than 300,000 individuals
was a 33% increase to the regular FY2009
who work at over 2,500 hospitals, medical
appropriations NIH received. NIH has also received
schools, universities, and other research
supplemental appropriations during several infectious
disease emergencies, such as for the Ebola and Zika
outbreaks. Given ongoing interest, a summary of the
FY2020 and FY2021 amounts for the Coronavirus
Disease 2019 (COVID-19) pandemic is provided in
Appendix B.

1 “Mandatory spending” is controlled by authorization acts; “discretionary spending” is controlled by appropriations
acts. For further information, see CRS Report R44582, Overview of Funding Mechanisms in the Federal Budget
Process, and Selected Examples.
2 The Public Health Service (PHS) also includes the Centers for Disease Control and Prevention (CDC), the Food and
Drug Administration (FDA), the Agency for Healthcare Research and Quality (AHRQ), the Health Resources and
Services Administration (HRSA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the
Indian Health Service (IHS), and the Agency for Toxic Substances and Disease Registry (ATSDR). HHS also made an
administrative decision to change the preexisting Office of the Assistant Secretary Preparedness and Response to a PHS
operating division, the Administration for Strategic Preparedness and Response.
3 For further information on the National Institutes of Health (NIH), see CRS Report R41705, The National Institutes of
Congressional Research Service

1

National Institutes of Health (NIH) Funding: FY1996-FY2023

institutions around the country.4 About 10% of the agency’s budget supports intramural research
(i.e., internal) conducted by nearly 6,000 NIH physicians and scientists, most of whom are
located on the NIH campus in Bethesda, MD.5
Funding Sources
The vast majority of NIH funding comes from annual discretionary appropriations. NIH
additionally receives some mandatory funding and other funding due to unique transfer or
budgetary rules, as explained below. The total funding available for NIH activities, taking account
of add-ons and transfers, is referred to as the NIH “program level.”6
Discretionary budget authority: NIH’s discretionary budget authority comes primarily from
annual LHHS Appropriations Acts, with an additional smaller amount for the Superfund Research
Program and related activities from the INT Appropriations Act.7
PHS Evaluation Set-Aside: Through LHHS appropriations, some funding is subject to the PHS
Evaluation Set-Aside or the “PHS Evaluation Tap” transfer authority.8 Authorized by Section 241
of the Public Health Service Act, the evaluation tap allows the Secretary of HHS, with the
approval of appropriators, to redistribute a portion of eligible PHS agency appropriations across
HHS for program evaluation and implementation purposes. The PHSA section limits the set-aside
to not less than 0.2% and not more than 1% of eligible program appropriations. However, LHHS
Appropriations Acts have commonly established a higher maximum percentage for the set-aside
and have directed transfers of specific amounts of “tap” funding to selected HHS programs. In the
context of NIH, these transfers have been made to National Institute of General Medical Sciences
in recent years.9 Since FY2010, and including in FY2023, this higher maximum set-aside level
has been 2.5% of eligible appropriations.10 By convention, totals in this report and NIH source
documents include amounts “transferred in” pursuant to the PHS tap as directed by appropriations

Health (NIH): Background and Congressional Issues.
4 NIH, “What We Do - Budget,” August, 2022, at https://www.nih.gov/about-nih/what-we-do/budget.
5 Ibid.
6 NIH program levels in this report reflect total funding for all Institutes and Centers (ICs), the Office of the Director
(OD), the PHS Evaluation Set-Aside (“PHS Evaluation Tap”), the Superfund Research Program, mandatory type I
diabetes research (provided in Public Health Service Act [PHSA] Section 330B), the nonrecurring expenses fund
(NEF), and, when applicable, and mandatory pandemic preparedness funding proposed in the FY2023 budget.
7 The Hazardous Substance Basic Research and Training Program (Superfund Research Program) funds research on the
health effects of exposures to hazardous substances and related solutions at the National Institute of Environmental
Health Sciences. It is authorized by 311(a) of the Comprehensive Environmental Response, Compensation, and
Liability Act of 1980 (42 U.S.C. §9660(a)) and Section 126(g) of the Superfund Amendments and Reauthorization Act
of 1986.
8 For more information on the PHS Evaluation Tap, or PHS Evaluation Set-Aside, see discussion in CRS Report
R44916, Public Health Service Agencies: Overview and Funding (FY2016-FY2018).
9 Prior to FY2015, NIH had traditionally been by far the largest net donor of tap funds, rather than a net recipient. The
joint explanatory statement accompanying the FY2015 omnibus explained this shift as being intended to ensure that tap
transfers are a “net benefit to NIH rather than a liability” and noted that this change was in response to a growing
concern at the loss of NIH funds to the tap. Joint Explanatory Statement, Proceedings and Debates of the
113th Congress, Second Session, Congressional Record, vol. 160, no. 151, Book II, December 11, 2014, p. H9832.
10 See Section 204 of Division H, Title II, of P.L. 117-328 for the FY2023 maximum set-aside level. The last time that
an appropriations act set the PHS tap percentage at a level other than 2.5% was in FY2009, when it was 2.4% (see P.L.
111-8). The FY2023 omnibus also retained a change to this provision, first included in the FY2014 omnibus, allowing
tap transfers to be used for the “evaluation and the implementation” of programs funded in the HHS title of the LHHS
Appropriations Act. Prior to FY2014, such provisions had restricted tap funds to the “evaluation of the
implementation” of programs authorized under the Public Health Service Act.
Congressional Research Service

2

link to page 13 National Institutes of Health (NIH) Funding: FY1996-FY2023

measures or proposed in the budget request, but do not include any amounts “transferred out”
under this same authority.
21st Century Cures Act Innovation Account: NIH also receives funding through LHHS
appropriations, subject to different budget enforcement rules than the rest of the NIH funding in
the act: appropriations to the NIH Innovation Account created by the 21st Century Cures Act (“the
Cures Act,” P.L. 114-255) to fund programs authorized by the act for FY2017 through FY2026.11
For appropriated amounts to the account—up the limit authorized for each fiscal year—the
amounts are subtracted from any cost estimate for enforcing discretionary spending limits (i.e.,
the budget caps). In effect, appropriations to the NIH Innovation Account as authorized by the
Cures Act are not subject to discretionary spending limits.12 The NIH Director may transfer these
amounts from the NIH Innovation Account to other NIH accounts, but only for the purposes
specified in the Cures Act. All amounts authorized by the Cures Act have been fully appropriated
to the Innovation Account from FY2017 to FY2023, including $1.085 billion for FY2023.
Mandatory Type I Diabetes Funding: In addition, NIH has received mandatory funding of $150
million annually that is provided in Public Health Service Act (PHSA) Section 330B for a special
program on type 1 diabetes research, most recently extended through FY2023 by the
Consolidated Appropriations Act, 2021 (P.L. 116-260; Division BB, Title III).
FY2022 Enacted Funding
On March 15, 2022, Congress and President Biden finalized NIH FY2022 appropriations by
enacting the Consolidated Appropriations Act, 2022 (P.L. 117-103), which included final FY2022
LHHS appropriations in Division H and Interior/Environment appropriations in Division G. The
enacted FY2022 NIH program level was made up of the following (see Table A-1):
 $43.65 billion in discretionary LHHS budget authority (nontransfer);
 $1.309 billion pursuant to the PHS program evaluation transfer;
 $83 million for the Superfund research program and related activities from
Interior/Environment appropriations; and
 $141 million in annual funding for the mandatory type 1 diabetes research
program.13
In total, the NIH FY2022 program level as enacted was $45.183 billion. In addition, the law
provided $1 billion for the Advanced Research Projects Agency for Health (ARPA-H) to a new
account under the Office of the Secretary with funding available until the end of FY2024. The
law allowed the HHS Secretary to place the new agency anywhere within the department within
30 days of enactment. On March 30, 2022, HHS Secretary Xavier Becerra submitted a notice to
the appropriations committees that ARPA-H was to reside within the NIH. Accounting for the
ARPA-H transfer, the NIH FY2022-enacted program level was $46.183 billion.

11 See section on 21st Century Cures Act in CRS Report R41705, The National Institutes of Health (NIH): Background
and Congressional Issues.
12 CRS Report R45778, Exceptions to the Budget Control Act’s Discretionary Spending Limits.
13 The FY2022 enacted amount for the mandatory type 1 diabetes research program differs from the amount for
FY2022 of $150 million in PHSA Section 330B, as amended in P.L. 116-260, Division BB, Title III. According to the
budget request, the FY2022 amount reflects sequestration of $8.55 million. See “Budget Mechanism Table,” p. 44, at
https://officeofbudget.od.nih.gov/pdfs/FY23/br/Overview%20of%20FY%202023%20Presidents%20Budget.pdf.
13 HHS, Budget in Brief: FY2023, pp. 53-54, https://www.hhs.gov/sites/default/files/fy-2023-budget-in-brief.pdf.

Congressional Research Service

3

link to page 13 link to page 13 National Institutes of Health (NIH) Funding: FY1996-FY2023

Advanced Research Projects Agency for Health (ARPA-H)
President Biden’s FY2022 budget request to Congress proposed the creation of an Advanced Research Projects
Agency for Health (ARPA-H) within the National Institutes of Health (NIH). The budget request proposed $6.5
bil ion for ARPA-H “to build platforms and capabilities to deliver cures for cancer, Alzheimer’s disease, diabetes,
and other diseases.” The agency was proposed to fol ow a Defense Advanced Research Projects Agency (DARPA)
approach to funding research. Funding was requested for a period of three years.
As mentioned here, the Consolidated Appropriations Act, 2022 (P.L. 117-103), provided $1 bil ion to HHS to
establish the Advanced Research Projects Agency for Health (ARPA-H). The law created a new ARPA-H account
at HHS, with funding available until September 30, 2024, and allowed the HHS Secretary to place the new agency
anywhere within the department within 30 days of enactment. On March 30, 2022, HHS Secretary Xavier Becerra
submitted a notice to the appropriations committees that ARPA-H was to reside within the NIH, while the ARPA-
H Director is to report directly to the HHS Secretary.
The Consolidated Appropriations Act, 2023 (P.L. 117-328), provided additional funding of $1.5 bil ion for ARPA-
H, available until the end of FY2025, in a separate account under the HHS Office of the Secretary. The law also
formally authorized the new agency as a part of the PREVENT Pandemics Act in Division FF, Title II of the law,
Section 2331. The new authorization places ARPA-H within NIH by statute.
For further information and analysis regarding ARPA-H, see CRS Report R47074, Advanced Research Projects Agency
for Health (ARPA-H): Congressional Action and Selected Policy Issues.
FY2023 Budget Request
President Biden’s FY2023 budget request would have provided NIH with a total program level of
$62.503 billion, an increase of $16.320 billion (+35.3%) from FY2022-enacted levels. The
proposed FY2023 program level would have provided the following (see Table A-1):
 $48.962 billion in discretionary LHHS budget authority (nontransfer);
 $1.272 billion pursuant to the PHS program evaluation transfer;
 $83 million for the Superfund research program and related activities from
Interior/Environment appropriations;
 $141 million in annual funding for the mandatory type 1 diabetes research
program;14 and
 $12.05 billion in proposed mandatory appropriations for pandemic preparedness,
to be available for five years.15
Under this request, approximately half of existing IC accounts would have received increases
compared with FY2022 enacted levels (see Appendix A). Funding for the National Institute on
Minority Health and Health Disparities (NIMHD) would have increased by the greatest
percentage amount (+$201 million, +43.7%), and funding for OD would have decreased by the
greatest amount (-$314 million, -12%). In addition, the full amount ($1.085 billion) authorized by
the 21st Century Cures Act for FY2023 (P.L. 114-255) would have been appropriated to the

14 This proposed amount for the mandatory type 1 diabetes research program differs from the already enacted amount
for FY2023 of $150 million in PHSA Section 330B, as amended in P.L. 116-260, Division BB, Title III. According to
the budget request, the FY2023 amount reflects sequestration of $8.55 million. See “Budget Mechanism Table,” p. 44,
at https://officeofbudget.od.nih.gov/pdfs/FY23/br/Overview%20of%20FY%202023%20Presidents%20Budget.pdf.

15 The FY2023 budget request proposed an HHS-wide total of $81.7 billion for pandemic preparedness to “transform
U.S. capabilities to prepare for and respond rapidly and effectively to future pandemics and other high consequence
biological threats.” The $12.05 billion directed to NIH would have been for “NIH research and development of
vaccines, diagnostics, and therapeutics against high priority viral families, biosafety and biosecurity, and to expand
laboratory capacity and clinical trial infrastructure.” See HHS, Budget in Brief: FY2023, p. 55, https://www.hhs.gov/
sites/default/files/fy-2023-budget-in-brief.pdf.
Congressional Research Service

4

link to page 13 National Institutes of Health (NIH) Funding: FY1996-FY2023

Innovation Account. The FY2023 budget request also proposed $5 billion for ARPA-H, an
increase of $4 billion from the FY2022 enacted level.16
Under the pandemic preparedness proposal, NIH would have been provided $12.05 billion in new
mandatory appropriations available for five years. This new appropriation made up 73.8% of the
proposed increase of $16.325 billion relative to FY2022 enacted program level. The pandemic
preparedness proposal generally did not designate specific amounts for NIH ICs, but describes a
number of activities the new funding would support, including vaccine and therapeutic
development, diagnostic test development and innovation, research infrastructure for clinical
trials, and laboratory biosafety and biosecurity.17
FY2023 Enacted Funding
On December 29, 2022, Congress and President Biden finalized NIH FY2023 appropriations by
enacting the Consolidated Appropriations Act, 2023 (P.L. 117-328), which includes final FY2023
LHHS appropriations in Division H and Interior/Environment appropriations in Division G. The
enacted FY2023 NIH program level is made up of the following (see Table A-1):
 $46.047 billion in discretionary LHHS budget authority;
 $1.412 billion pursuant to the PHS program evaluation transfer;
 $83 million for the Superfund research program and related activities from
Interior/Environment appropriations; and
 $141 million in annual funding for the mandatory type 1 diabetes research
program.18
In total, the NIH FY2023 program level as enacted is $47.683 billion. In addition, the law
provides $1.5 billion for ARPA-H in an account under the Office of the Secretary with funds
available until the end of FY2025. According to the new authorization for ARPA-H, also enacted
in Consolidated Appropriations Act, 2023 (P.L. 117-328; Division FF; Title II, Section 2331), the
new agency is established within NIH.
Accounting for the ARPA-H, the NIH FY2023 enacted program level is $49.183 billion. This
FY2023 NIH program level is a $3 billion increase (+6.5%) relative to the FY2022 enacted
program level of $46.183 billion. The FY2022 enacted total for NIH is also $13.324 billion
(-21.3%) less than the FY2023 budget request. The $13.324 billion difference between FY2023
enacted and FY2023 requested program level is primarily because Congress did not fund the
Pandemic Preparedness proposal and also funded ARPA-H at a lower level than requested. The
President’s budget requested $5 billion for ARPA-H, while in the FY2023 enacted law, ARPA-H
instead receives $1.5 billion.
In FY2023, all IC accounts receive an increase relative to FY2022 funding levels. For the
Innovation Account, the full amount authorized by the 21st Century Cures Act ($1.085 billion) is
appropriated.

16 Congressional Record, vol. 168, no. 198, Book II, December 20, 2022, pp. S9145-S9147, S8853
17 NIH, Congressional Justification: FY2023, pp. 17-20, https://officeofbudget.od.nih.gov/pdfs/FY23/br/
Overview%20of%20FY%202023%20Presidents%20Budget.pdf.
18 The FY2023 enacted amount for the mandatory type 1 diabetes research program differs from the appropriated
amount for FY2023 of $150 million in PHSA Section 330B, as amended in P.L. 116-260, Division BB, Title III.
According to the budget request, the FY2023 amount reflects sequestration of $8.55 million. See “Budget Mechanism
Table,” p. 44, at https://officeofbudget.od.nih.gov/pdfs/FY23/br/
Overview%20of%20FY%202023%20Presidents%20Budget.pdf.
Congressional Research Service

5

link to page 11 link to page 10 link to page 10 link to page 11 National Institutes of Health (NIH) Funding: FY1996-FY2023

Trends
Table 1 outlines NIH program level funding from FY1996 until FY2023. Figure 1 illustrates
funding trends in both current (also called nominal dollars) and projected constant (i.e., inflation-
adjusted) FY2022 dollars (funding shown is total budget authority).
NIH has seen periods of high and low funding growth. Between FY1996 and FY1998, funding
for NIH grew from $11.928 billion to $13.675 billion (nominal dollars). Over the next five years,
Congress and the President doubled the NIH budget to $27.167 billion in FY2003. In each of
FY1999 through FY2003, NIH received annual funding increases of 14% to 16%. From FY2003
to FY2015, NIH funding increased more gradually in nominal dollars.19 In some years, (FY2006,
FY2011, and FY2013) funding for the agency decreased in nominal dollars.20 From FY2016
through FY2023, NIH has seen funding increases each year. The largest increase was from
FY2017 to FY2018, where the program level increased by $3.010 billion (+8.8%), making this
the largest percentage increase since FY2003. The FY2023 program level represents a 6.5%
increase over the FY2022 level (including ARPA-H funding).
The lower half of Figure 1 shows NIH funding adjusted for inflation (in projected constant
FY2022 dollars) using the Biomedical Research and Development Price Index (BRDPI).21 It
shows that the purchasing power of NIH funding initially peaked in FY2003 (the last year of the
five-year doubling period) and then declined fairly steadily for more than a decade until
consecutive funding increases were provided in each of FY2016 through FY2023. The FY2023
program level is 1.2% greater than the peak FY2003 program level, although the FY2023
program level includes funding for a new agency, ARPA-H, and therefore may not be comparable
to the FY2003 level. When excluding funding for ARPA-H, the FY2023 level is 1.9% less than
the FY2003 level.

19 Amounts shown in Table 1 include appropriations for the Global Fund to Fight AIDS, TB, and Malaria (FY2002-
FY2011) that were subject to transfer-out. As of FY2012, NIH no longer receives appropriations for the National
Institute of Allergy and Infectious Diseases (NIAID) identifying resources for the Global Fund; this responsibility was
transferred to another federal agency. For further details on the amounts transferred out by fiscal year, see the
“Supplemental Appropriation Data Table” for “History of Congressional Appropriations, Fiscal Years 2000-2012” at
http://officeofbudget.od.nih.gov/approp_hist.html.
20 For instance, the FY2006 total was 0.1% lower than the previous year, the first time that NIH appropriations had
decreased since FY1970; the FY2011 total, provided in the Full-Year Continuing Appropriations Act, 2011 (P.L. 112-
10), was 1.0% less than the previous fiscal year; the FY2013 total, provided in the Consolidated and Further
Continuing Appropriations Act, 2013 (P.L. 113-6), was reduced by the March 2013 sequestration and a transfer of
funding under the authority of the HHS Secretary ($1.553 billion and $173 million, respectively), resulting in a budget
that was 5.0% lower than the prior year.
21 The index is developed for NIH by the Bureau of Economic Analysis of the Department of Commerce. It reflects the
increase in prices of the resources needed to conduct biomedical research, including personnel services, supplies, and
equipment. It indicates how much the NIH budget must change to maintain purchasing power. See “NIH Price
Indexes,” at https://officeofbudget.od.nih.gov/gbiPriceIndexes.html.
Congressional Research Service

6

link to page 13 link to page 20

National Institutes of Health (NIH) Funding: FY1996-FY2023

Figure 1. NIH Funding, FY1996-FY2023
Program Level Funding in Current and Projected Constant (FY2022) Dollars.

Source: Sources used for FY2023 and FY2022 program levels are in Table A-1. The FY2021 (and earlier)
program levels are from NIH Budget Office, Appropriations History by Institute/Center (1938 to Present), at
http://officeofbudget.od.nih.gov/approp_hist.html. Inflation adjustment reflects the Biomedical Research and
Development Price Index (BRDPI), updated March 2022, at https://officeofbudget.od.nih.gov/
gbiPriceIndexes.html.
Notes: By convention, program level totals include amounts “transferred in” pursuant to PHS tap but do not
include any amounts “transferred out” under this same authority. Program level includes all budget authority,
including appropriations for the Global Fund to Fight AIDS, TB, and Malaria (FY2002-FY2011) that were subject
to transfer-out. As of FY2012, NIH no longer receives appropriations for the National Institute of Allergy and
Infectious Diseases (NIAID) identifying resources for the Global Fund; this responsibility was transferred to
another federal agency. In general, amounts provided to NIH designated for emergency requirements are
excluded from these totals (e.g., the FY2020 and FY2021 amounts do not include the amounts provided in the
coronavirus supplemental appropriations acts, summarized in Appendix B).
Congressional Research Service

7

link to page 12 link to page 13 link to page 11 National Institutes of Health (NIH) Funding: FY1996-FY2023

Table 1. NIH Funding, FY1996-FY2023
Program Level Funding in Current and Constant (FY2022) Dollars (Billions)
Program Level
Projected
Program Level
Constant
% Relative to
Fiscal Year
Current $
% Change
FY2022 $
FY2003a
1996
11.928
5.6%
25.763

1997
12.741
6.8%
26.774

1998
13.675
7.3%
27.795

1999
15.629
14.3%
30.792

2000
17.841
14.1%
33.886

2001
20.459
14.7%
37.608

2002
23.321
14.0%
41.496

2003
27.167
16.5%
46.697

2004
28.037
3.2%
46.461
-0.5%
2005
28.594
2.0%
45.611
-2.3%
2006
28.560
-0.1%
43.541
-6.8%
2007
29.179
2.2%
42.858
-8.2%
2008
29.607
1.5%
41.543
-11.0%
2009
30.545
3.2%
41.640
-10.8%
2010
31.238
2.3%
41.328
-11.5%
2011
30.916
-1.0%
39.764
-14.8%
2012
30.861
-0.2%
39.191
-16.1%
2013
29.316
-5.0%
36.545
-21.7%
2014
30.143
2.8%
36.785
-21.2%
2015
30.311
0.6%
36.253
-22.4%
2016
32.311
6.6%
37.822
-19.0%
2017
34.301
6.2%
39.134
-16.2%
2018
37.311
8.8%
41.532
-11.1%
2019
39.313
5.4%
42.855
-8.2%
2020
41.690
6.0%
44.666
-4.4%
2021
42.941
3.0%
44.885
-3.9%
2022
46.183
7.5%
46.183
-1.1%
2023
49.183
6.5%
47.236
1.2%
Sources: Sources used for FY2023 and FY2022 program levels are in Table A-1. The FY2021 (and earlier)
program levels are from NIH Budget Office, Appropriations History by Institute/Center (1938 to Present), at
http://officeofbudget.od.nih.gov/approp_hist.html. Inflation adjustment reflects the Biomedical Research and
Development Price Index (BRDPI), updated February 2023, at https://officeofbudget.od.nih.gov/
gbiPriceIndexes.html.
Notes: By convention, budget tables, such as Table 1, include amounts “transferred in” pursuant to PHS tap
but do not include any amounts “transferred out” under this same authority. Program level includes all budget
authority, including appropriations for the Global Fund to Fight AIDS, TB, and Malaria (FY2002-FY2011) that
Congressional Research Service

8

link to page 20 National Institutes of Health (NIH) Funding: FY1996-FY2023

were subject to transfer-out. As of FY2012, NIH no longer receives appropriations for the National Institute of
Allergy and Infectious Diseases (NIAID) identifying resources for the Global Fund; this responsibility was
transferred to another federal agency. In general, amounts provided to NIH for emergency requirements are
excluded from these totals (e.g., the FY2020 and FY2021 amounts do not include the amounts provided in the
coronavirus supplemental appropriations acts, summarized in Appendix B). FY2022 and FY2023 amounts
include funding for the Advanced Research Projects Agency for Health (ARPA-H). PB denotes “President’s
Budget.”
a. FY2003 was the year that NIH received the most program level funding (prior to FY2022) in 2022 constant
dol ars.
Congressional Research Service

9

link to page 14 link to page 14 link to page 14 link to page 14 link to page 14 link to page 14 link to page 14 National Institutes of Health (NIH) Funding: FY1996-FY2023

Appendix A. NIH Funding Details
Table A-1. National Institutes of Health Funding
(budget authority, in millions of dollars)
FY2022
FY2023
FY2023
Institutes/Centers
Enacted
Request
Enacted
Cancer Institute (NCI)
$6,913
$6,714
$7,320
Heart, Lung, and Blood Institute (NHLBI)
$3,808
$3,823
$3,982
Dental/Craniofacial Research (NIDCR)
$501
$513
$520
Diabetes/Digestive/Kidney (NIDDK)a
$2,204
$2,206
$2,301
Neurological Disorders/Stroke (NINDS)
$2,611
$2,768
$2,814
Allergy/Infectious Diseases (NIAID)
$6,323
$6,268
$6,562
General Medical Sciences (NIGMS)b
$1,783
$1,826
$1,827
Child Health/Human Development (NICHD)
$1,683
$1,675
$1,749
National Eye Institute (NEI)
$864
$853
$897
Environmental Health Sciences (NIEHS)c
$842
$932
$914
National Institute on Aging (NIA)
$4,220
$4,011
$4,408
Arthritis/Musculoskeletal/Skin Diseases
$656
$676
$685
(NIAMS)
Deafness/Communication Disorders
$515
$509
$534
(NIDCD)
Alcohol Abuse/Alcoholism (NIAAA)
$574
$567
$595
Nursing Research (NINR)
$181
$199
$198
National Institute on Drug Abuse (NIDA)
$1,595
$1,843
$1,663
National Institute of Mental Health (NIMH)
$2,217
$2,211
$2,338
Human Genome Research Institute (NHGRI)
$639
$629
$663
Biomedical Imaging/Bioengineering (NIBIB)
$425
$419
$441
Complementary/Integrative Health (NCCIH)
$159
$183
$170
Minority Health/Health Disparities (NIMHD)
$459
$660
$524
Fogarty International Center (FIC)
$87
$96
$95
National Library of Medicine (NLM)
$479
$472
$498
Advancing Translational Sciences (NCATS)
$882
$874
$923
Office of Director (OD)d
$2,629
$2,315
$2,656
(Common Fund)
($657)
($646)
($772)
(Office for Research on Women’s Health)
($59)
($53)
($76)
Innovation Accounte
$150
$419
$419
Buildings and Facilities (B&F)
$250
$300
$350
Research Quality
—
—

Advanced Research Projects Agency for Health
$1,000f
$5,000
$1,500f
(ARPA-H)
Subtotal, NIH (LHHS Discretionary
$44,650
$48,962
$47,547
BA)
Congressional Research Service

10

link to page 14 link to page 14 link to page 14 link to page 14 link to page 13 link to page 20 National Institutes of Health (NIH) Funding: FY1996-FY2023

FY2022
FY2023
FY2023
Institutes/Centers
Enacted
Request
Enacted
PHS Program Evaluation (provided to
$1,309
$1,272
$1,412
NIGMS)
Superfund (Interior approp. to NIEHS)g
$83
$83
$83
Mandatory type 1 diabetes funds (to
$141
$141
$141
NIDDK)h
Pandemic Preparednessi (proposed
—
$12,050
—
mandatory)i
NIH Program Level
$46,183
$62,508
$49,183
Source: The FY2023 enacted, FY2023 request and FY2022 enacted amounts are from Congressional Record, vol.
168, no. 198, Book II, December 20, 2022, pp. S9145-S9147, S8853.
Notes: Totals may differ from the sum of the components due to rounding. Amounts in table may differ from
actuals in many cases. By convention, budget tables such as Table A-1 do not subtract the amount of transfers
to the evaluation tap from the agencies’ appropriation. In general, amounts provided to NIH for emergency
requirements are excluded from these totals (e.g., FY2021 amounts do not include the amounts provided in the
coronavirus supplemental appropriations acts, summarized in Appendix B).
a. Amounts for the NIDDK do not include mandatory funding for type 1 diabetes research (see note h).
b. Amounts for NIGMS do not include funds from PHS Evaluation Set-Aside (§241 of the PHS Act).
c. Amounts for NIEHS do not include Interior/Environment Appropriations amount for Superfund research
(see note g).
d. Includes $12.6 mil ion transfer from the Pediatric Research Initiative Fund (PRIF) as authorized by the
Gabriella Mil er Kids First Research Act P.L. 113-94).
e. The amount shown for the NIH Innovation Account in each column represents only a portion of the total
appropriation to the account: $496 mil ion for FY2022; $1.085 bil ion for FY2023. The remaining funds for
this account are reflected, where applicable, into the totals for other ICs. For FY2022, this includes $194
mil ion to NCI for cancer research and $76 mil ion to each of NINDS and NIMH for the BRAIN Initiative
($152 mil ion total for BRAIN). For FY2023, this includes $216 mil ion to NCI for cancer research and $225
mil ion to each of NINDS and NIMH for the BRAIN Initiative ($450 mil ion total).
f.
ARPA-H was funded under a separate account under the Office of the Secretary in both FY2022 and
FY2023. In FY2022, a proviso accompanying the appropriation gave HHS Secretary Becerra the ability to
transfer the new agency anywhere within the department within 30 days of enactment. On March 30, 2022,
HHS Secretary Becerra submitted a notice to the appropriations committees that ARPA-H is to reside
within the NIH; therefore, ARPA-H is shown within NIH in this table. For FY2023, ARPA-H authorizing
legislation in Division FF (P.L. 117-328) established it as a component of NIH. Therefore, ARPA-H is shown
within the NIH program level in this report.
g. This is a separate account in the Interior/Environment appropriations for NIEHS research activities related
to Superfund research.
h. Mandatory funds are available to NIDDK for type 1 diabetes research under PHSA Section 330Bm, which
was most recently extended through FY2023 by the Consolidated Appropriations Act, 2021 (P.L. 116-260;
Division BB, Title II). The FY2022 and FY2023 amounts for the type I diabetes research program ($141
mil ion) are lower than the enacted funding levels for FY2022 and FY2023 ($150 mil ion). According to the
budget request, the FY2022 and FY2023 amounts reflect sequestration of $8.55 mil ion. See “Budget
Mechanism Table,” p. 44 in https://officeofbudget.od.nih.gov/pdfs/FY23/br/
Overview%20of%20FY%202023%20Presidents%20Budget.pdf.
i.
The FY2023 request proposed new mandatory funding for pandemic preparedness to be available for five
years. The request proposed an HHS-wide total of $81.7 bil ion for pandemic preparedness, with $12.05
bil ion of the total designated for NIH.
Program-Specific Funding
In recent years, Congress and the President have increasingly specified funding levels for
programs or research areas within NIH accounts throughout the budget and appropriations
process. Congress uses appropriations report language to designate funding for specified
Congressional Research Service

11

link to page 15 link to page 19 link to page 19 National Institutes of Health (NIH) Funding: FY1996-FY2023

purposes, whereas the President proposes amounts in his annual budget request.22 This is a
relatively new practice that has expanded since FY2015.23 For the most part, Congress does not
specify NIH funding for particular diseases or areas of research in the appropriations process and
instead allows the ICs to award funding within their mission areas based on their own strategic
planning and priority-setting processes. Research funding is generally awarded on a flexible and
competitive basis through various funding mechanisms intended to balance scientific and health
priorities.24
In FY2023, Congress used appropriations report language to specify a certain amount of IC
funding for designated purposes, as summarized in Table A-2. Most of these amounts are
specified in the explanatory statement accompanying enacted appropriations;25 in a few cases,
amounts specified in the House Appropriations report (H.Rept. 117-96) are incorporated by
reference.26 Sometimes the language specifies a certain amount for a certain purpose; in other
cases, the language provides increased or additional funding. The appropriations reports also
include many additional statements directing the agency to prioritize certain programs or areas of
research, as well as statements expressing the opinion or concerns of Congress regarding NIH.
These broad statements are not summarized here.
Table A-2. Specified NIH Funding Levels in FY2023 Explanatory Statement
Institute/Center
Program/Activity
Amount
National Cancer Institute
Childhood Cancer Data Initiative (CCDI)
No less than $50 mil ion
(NCI)
including no less than $750
thousand to continue to
support enhancement of the
CCDI Molecular
Characterization Initiative.
Childhood Cancer Survivorship, Treatment
No less than $30 mil ion
Access, and Research (STAR) Act
(including $2 mil ion for cancer
registry case capture efforts for
childhood and adolescent
cancers.*)
NCI Paylines
An increase of $150 mil ion
Health Disparities Researcha
An increase of $10 mil ion
National Heart, Lung, and
Community Engagement Alliance Against
$30 mil ion
Blood Institute (NHLBI)
COVID–19 Disparities (CEAL) Initiative
Health Disparities Researcha
An increase of $15 mil ion

22 For a general overview, see CRS Report R44124, Appropriations Report Language: Overview of Components and
Development, and CRS Report R47019, The Executive Budget Process: An Overview.
23 As recently as December 2014, the explanatory statement on the FY2015 omnibus stipulated, “In keeping with
longstanding practice, the agreement does not recommend a specific amount of NIH funding for this purpose
[Alzheimer’s disease] or for any other individual disease. Doing so would establish a dangerous precedent that could
politicize the NIH peer review system. Nevertheless, in recognition that Alzheimer’s disease poses a serious threat to
the Nation’s long-term health and economic stability, the agreement expects that a significant portion of the
recommended increase for NIA should be directed to research on Alzheimer's. The exact amount should be determined
by scientific opportunity of additional research on this disease and the quality of grant applications that are submitted
for Alzheimer’s relative to those submitted for other diseases.” See Congressional Record, daily edition, vol. 160, no.
151, Book II (December 11, 2014), p. H9832.
24 CRS Report R41705, The National Institutes of Health (NIH): Background and Congressional Issues.
25 Congressional Record, vol. 168, no. 198, Book II, December 20, 2022, pp. S8881-S8887, S8853.
26 House report amounts cited where not superseded by the explanatory statement per direction in the explanatory
statement, “Unless otherwise noted, the language set forth in H.Rept. 117-403 carries the same weight as language
included in this explanatory statement and should be complied with unless specifically addressed to the contrary in this
explanatory statement” (Congressional Record, vol. 168, no. 198, Book II, December 20, 2022, p. S8874).
Congressional Research Service

12

link to page 19 link to page 19 link to page 19 National Institutes of Health (NIH) Funding: FY1996-FY2023

Institute/Center
Program/Activity
Amount
Valvular Heart Disease Research
$20 mil ion
National Institute of
Pain Management Researcha
An increase of $9 mil ion
Dental and Craniofacial
Research (NIDCR)
National Institute of
Special Diabetes Program
$8.55 mil ion to restore cuts
Diabetes and Digestive
for SDP from sequestration
and Kidney Diseases
Pain Management Research
An increase of $5 mil ion
(NIDDK)
National Institute of
Alzheimer’s Disease and Alzheimer’s Disease
An increase in $75 mil ion for
Neurological Disorders
Related Dementias (AD/ADRD)
NINDS out of the $226
and Stroke (NINDS)
increase for AD/ADRD across
NIH
HEAL Initiative (opioids, stimulants, and pain
No less than $280.295 mil ion,
management)
an increase of $10 mil ion
Undiagnosed Diseases Network (UDN)
$18 mil ion
National Institute of
Consortium of Food Allergy Research
$12.1 mil ion, an increase of $3
Allergy and Infectious
(CoFAR)
mil ion
Diseases (NIAID)
Regional biocontainment laboratories (RBL)
$52 mil ion of which non less
than $1 mil ion shall be
provided to each of the 12
RBLs to support the
maintenance of a capable
research workforce, facilities,
and equipment.
Centers for AIDS Research (CFARS)a
$71 mil ion
Responding to infectious diseases/Antimicrobial
No less than $565 mil ion, an
Resistance
increase of $25 mil ion
Universal flu vaccine
No less than $270 mil ion, an
increase of $25 mil ion
Health Disparities Researcha
$10 mil ion
National Institute of
Health Disparities Research
An increase of $5 mil ion
General Medical Sciences
Increasing diversity in biomedical research
An increase of $10 mil ion
(NIGMS)
Institutional Development Award (IDeA) Program $425.956 mil ion, an increase of
$15.503 mil ion
Eunice Kennedy Shriver
Heath Impacts on Children of Technology and
$15 mil ion
National Institute of Child Social Media Use
Health and Human
Impact of COVID–19 on children
An increase of $2.5 mil ion
Development (NICHD)
Impact of COVID-19 on Pregnant and Lactating
An increase of $3 mil ion
Women
Implementing a Maternal Health and Pregnancy
No less than $43.4 mil ion
Outcomes Vision for Everyone (IMPROVE)
Initiative
National Institute of
Additional Research
An increase of $40 mil ion
Environmental Health
Sciences (NIEHS)
Congressional Research Service

13

link to page 19 link to page 19 link to page 19 link to page 19 link to page 19 National Institutes of Health (NIH) Funding: FY1996-FY2023

Institute/Center
Program/Activity
Amount
National Institute on
Alzheimer’s disease and related dementias
An increase in $151 mil ion for
Aging (NIA)
NINDS out of the $226
increase for AD/ADRD,
including $1.5 mil ion for a
National Academies of
Sciences, Engineering, and
Medicine (NASEM) report on
research priorities on
AD/ADRD informed by an
expert panel.
National Institute of
Opioids and pain/pain management researcha
An increase of $5 mil ion
Arthritis and
Musculoskeletal and Skin
Diseases (NIAMS)
National Institute on
HEAL Initiative (opioids, stimulants, and pain
No less than $355.295 mil ion
Drug Abuse (NIDA)
management)
Pain and pain management
Additional $10 mil ion
Youth and Perinatal Marijuana Usea
$2 mil ion to enter into
contract with NASEM to study
youth and perinatal marijuana
use
National Institute of
Impact of COVID on mental health
An increase of $5 mil ion
Mental Health (NIMH)
Mental Health Treatment Research
An increase of $5 mil ion
National Institute of
Health disparities research
An increase of $10 mil ion
Nursing Research (NINR)
National Institute on
Chronic Disease Centers
An additional $11 mil ion
Minority Health and
Health disparities research
An increase of $25 mil ion
Health Disparities
Research Centers in Minority Institutions
$88.765 mil ion
(NIMHD)
Coordination Network
Research Endowment Program
$12 mil ion
National Center for
Pain and pain management researcha
An additional $5 mil ion
Complementary and
Integrative Health
(NCCIH)
National Center for
Clinical and Translational Science Awards
$629.56 mil ion, an increase of
Advancing Translational
(CTSAs)
$22.914 mil ion
Sciences (NCATS)
Cures Acceleration Network (CAN)
$70 mil ion
John E. Fogarty
Health disparities researcha
An increase of $5 mil ion
International Center (FIC)
Office of the Director
Administration Offices
$4.55 mil ion
(OD)/ Multi-Institute
Amyotrophic lateral sclerosis (ALS)
$75 mil ion for implementation
Research Initiatives
of the Accelerating Access to
Critical Therapies for ALS Act
(P.L. 117-79), an increase of
$50 mil ion.
All of Us Precision Medicine Initiativea
$541 mil ion, including $419
mil ion from the Innovation
Account
Congressional Research Service

14

link to page 19 link to page 19 link to page 19 National Institutes of Health (NIH) Funding: FY1996-FY2023

Institute/Center
Program/Activity
Amount
Artificial Intelligence/Machine Learning (AI/ML)
$135 mil ion including $85
mil ion for Office of Data
Science Strategy (an increase of
$15 mil ion), $50 mil ion for
AI/ML focused investment, and
$3 mil ion for the Office of
Portfolio Analysis
Grants for biomedical research facilities
$80 mil ion
Brain Research through Advancing Innovative
$680 mil ion,b including $95
Neurotechnologies (BRAIN) Initiative
mil ion for the Human Brain
Cell Atlas, $10 mil ion for the
Armamentarium for Brain Cell
Access, and $30 mil ion for the
Brain Connectivity Map
Foreign Threats to Research
$5 mil ion transferred from
NIH to the Inspector General
to conduct investigation into
foreign threats to research*
Common Fund
Increase of $65 mil ion
Office of Nutrition Research (ONR)a
$40 mil ion
Cybersecurity
$265 mil ion an increase of $40
mil ion
Development Delays
$100 mil ion
Environmental Influences on Child Health
$180 mil ion, the same level as
Outcomes (ECHO)a
FY2022
Firearm injury and mortality prevention research
$12.5 mil ion, the same level as
FY2022
HHS Office of Extramural Research allocation for
$2.5 mil ion
foreign influence
NASEM Study on Heritable Genetic Information
$1.3 mil ion
Investigation of Co-Occurring Conditions Across
No less than $90 mil ion
the Lifespan to Understand Down Syndrome
(INCLUDE)
Office of AIDS Research, for HIV/AIDS research
An increase of $100 mil ion
Office of Research on Women's Health (ORWH)
$76.48 mil ion, including $5
mil ion, an increase of $1
mil ion, for the Building
Interdisciplinary Research
Careers in Women’s Health
(BIRCWH) program.

$10 mil ion to establish an
Office of Autoimmune Disease
Research (OADR).

$2 mil ion to contract NASEM
on a study on gaps in
knowledge of women’s health.
Office of the Chief Officer for Scientific
$22.415 mil ion
Workforce Diversity (COSWD)
Source: Congressional Record, vol. 168, no. 198, Book II, December 20, 2022, pp. S8881-S8887, S8853. House
report amounts cited where not superseded by the explanatory statement per direction in the explanatory
statement, “Unless otherwise noted, the language set forth in H.Rept. 117-403 carries the same weight as
Congressional Research Service

15

link to page 15 National Institutes of Health (NIH) Funding: FY1996-FY2023

language included in this explanatory statement and should be complied with unless specifically addressed to the
contrary in this explanatory statement” (p. S8874).
Notes: Table does not include amounts already shown in Table A-2. Dol ar amounts are at the level of detail
used in the appropriations report text.
a. From H.Rept. 117-96.
b. Amount includes $450 mil ion from the Innovation Account for the BRAIN Initiative as authorized by the
Cures Act (split between NINDS and NIMH in FY2022 appropriations).
Congressional Research Service

16

National Institutes of Health (NIH) Funding: FY1996-FY2023

Appendix B. Coronavirus Supplemental
Appropriations (FY2020 and FY2021) and Additional
American Rescue Plan Act funding
NIH received FY2020 and FY2021 emergency supplemental appropriations to several IC
accounts and as transfers from the Public Health and Social Services Emergency Fund (PHSSEF)
account as provided by four coronavirus supplemental appropriations acts:27
 First Measure: Division A of the Coronavirus Preparedness and Response
Supplemental Appropriations Act, 2020 (P.L. 116-123), enacted on March 6,
2020.
 Second Measure: Division B of the Coronavirus Aid, Relief, and Economic
Security Act (CARES Act, P.L. 116-136), enacted on March 27, 2020.
 Third Measure: Division B of the Paycheck Protection Program and Health
Care Enhancement Act (PPPHCEA, P.L. 116-139), enacted on April 24, 2020.
 Fourth Measure: Division M of Consolidated Appropriations Act, 2021 (P.L.
116-260), enacted on December 27, 2020.
NIH received a total of $3.031 billion to NIH IC accounts, along with directed transfers from the
PHSSEF account to NIH accounts totaling not less than $1.806 billion. Accounting for transfers,
NIH received a total of at least $4.837 billion (see text box below for information on American
Rescue Plan Act funding). All appropriations to NIH accounts are available until September 30,
2024, and all transfers from the PHSSEF are available until expended. This funding was primarily
provided in three categories:
Broadly Available Funding. In the first (P.L. 116-123) and third measure (CARES Act; P.L. 116-
136), funding was made available to several NIH IC accounts “to prevent, prepare for and
respond to coronavirus, domestically and internationally.” NIH IC accounts that received broadly
available funds and their totals include the following:
 National Institute of Allergy and Infectious Diseases (NIAID): $1.542 billion,
including $836 million in the first measure and $706 million in the CARES Act.
Some transfers or set-asides were directed for specific purposes in the NIAID
appropriations. The first measure directed a transfer of not less than $10 million
to the National Institute of Environmental Health Sciences (NIEHS) for “worker-
based training to prevent and reduce exposure of hospital employees, emergency
first responders, and other workers who are at risk of exposure to coronavirus
through their work duties.” The third measure set aside not less than $156 million
of the total for “the study of, construction of, demolition of, renovation of, and
acquisition of equipment for, vaccine and infectious diseases research facilities of
or used by NIH, including the acquisition of real property.”
 National Heart, Lung, and Blood Institute (NHLBI): $103 million in the
CARES Act.
 National Institute of Biomedical Imaging and Bioengineering (NIBIB): $60
million in the CARES Act.

27 NIH did not receive supplemental appropriations from the Families First Coronavirus Response Act (FFCRA, P.L.
116-127), enacted on March 18, 2020.
Congressional Research Service

17

National Institutes of Health (NIH) Funding: FY1996-FY2023

 National Library of Medicine (NLM): $10 million in the CARES Act.
 National Center for Advancing Translational Sciences (NCATS): $36 million
in the CARES Act.
 Office of the Director (OD): $30 million in the CARES Act.
Diagnostic Testing Research and Development (R&D). In the fourth and fifth measures, NIH
received funding for specific purposes related to diagnostic test R&D. This funding was directed
to NIH as “not less than” transfers from the PHSSEF account in the fourth measure, and directly
to the OD account in the fifth measure. These amounts included the following:
 National Cancer Institute (NCI): Transfer of not less than $306 million from
PHSSEF to NCI “to develop, validate, improve, and implement serological
testing and associated technologies” in the fourth measure.
 NIBIB: Transfer of not less than $500 million from PHSSEF to NIBIB “to
accelerate research, development, and implementation of point of care and other
rapid testing related to coronavirus” in the fourth measure.
 OD: Transfer of not less than $1 billion from PHSSEF to OD “to develop,
validate, improve, and implement testing and associated technologies; to
accelerate research, development, and implementation of point of care and other
rapid testing; and for partnerships with governmental and non-governmental
entities” in the fourth measure. In the fifth measure, not less than $100 million of
the $1.250 billion total provided to the OD account is for “the Rapid Acceleration
of Diagnostics.”
NIH’s Rapid Acceleration of Diagnostics (RADx) initiative is an effort to innovate and scale up
COVID-19 diagnostic technologies. As communicated to CRS, the $1.5 billion total for NIBIB
and OD in the fourth measure was used to support RADx initially, with additional funds in the
fifth measure as specified above.28
Long-Term Studies of COVID-19. The fifth measure directed $1.15 billion of the total $1.25
billion provided to the OD account “for research and clinical trials related to long-term studies of
COVID-19.” The $1.15 billion has since been directed toward NIH’s REsearching COVID to
Enhance Recovery (RECOVER) Initiative, a large coordinated research initiative to study Long
COVID.29 The fifth measure also allows the total $1.25 billion appropriation to OD to be
transferred to other IC accounts (in addition to other HHS transfer authorities in the law).

28 CRS communication with NIH, July 24, 2020.
29 See “How is RECOVER being paid for” at RECOVER: Frequently Asked Questions, https://recovercovid.org/
faqs#paid. As reported by the Government Accountability Office (GA)-22-105497), HHS transferred $1,063.5 million
of the $1.25 appropriation for NIH OD in the fifth measure to the Administration for Children and Families’
Unaccompanied Children Program (see “Appendix: HHS COVID-19 Funding,” GAO-22-105397). NIH’s RECOVER
website states that “the primary funding source for RECOVER has changed to the American Rescue Plan (ARP) Act of
2021 (Sec. 2401), the $1.15 billion budget remains and NIH RECOVER research activities have neither stopped nor
had any delays.”
Congressional Research Service

18

National Institutes of Health (NIH) Funding: FY1996-FY2023

American Rescue Plan Act of 2021 (ARPA; P.L. 117-2) Appropriations
The ARPA did not provide any mandatory appropriations directly to NIH but made available several
appropriations that could be allocated to NIH. For example, $6.05 bil ion was provided to the HHS Secretary in
mandatory appropriations (i.e., direct appropriations) for research, development, manufacturing, production, and
the purchase of vaccines, therapeutics, and ancil ary medical products and supplies—available to address COVID-
19, SARS-CoV-2 or its variants, and any disease with potential for creating a pandemic (Title II, Section 2303). The
HHS Secretary can allocate a portion of these funds to NIH accounts at his discretion. In addition, NIH has
reported that the HHS Secretary has allocated other ARPA funding in Section 2401 toward the RECOVER
Initiative (see above) after an initial transfer of $1,063.5 from NIH to HHS’s Administration for Children and
Families’ Unaccompanied Children Program of the original appropriation for that program in the fifth measure
(see footnote 27).

Congressional Research Service

19

National Institutes of Health (NIH) Funding: FY1996-FY2023

Appendix C. Acronyms and Abbreviations
Acronym/
Abbreviation
Organization/Term
ARPA-H
Advanced Research Projects Agency for Health
DARPA
Defense Advanced Research Projects Agency
DOD
Department of Defense
FIC
Fogarty International Center
FY
Fiscal Year
IC
Institutes and Centers
NASEM
National Academies of Sciences, Engineering, and Medicine
NCATS
National Center for Advancing Translational Sciences
NCCIH
National Center for Complementary and Integrative Health
NCI
National Cancer Institute
NEF
Nonrecurring Expenses Fund
NEI
National Eye Institute
NHGRI
National Human Genome Research Institute
NHLBI
National Heart, Lung, and Blood Institute
NIA
National Institute on Aging
NIAAA
National Institute on Alcohol Abuse and Alcoholism
NIAID
National Institute of Allergy and Infectious Diseases
NIAMS
National Institute of Arthritis and Musculoskeletal and Skin Diseases
NIBIB
National Institute of Biomedical Imaging and Bioengineering
NICHD
National Institute of Child Health and Human Development
NIDA
National Institute on Drug Abuse
NIDCD
National Institute on Deafness and Other Communication Disorders
NIDCR
National Institute of Dental and Craniofacial Research
NIDDK
National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS
National Institute of Environmental Health Sciences
NIGMS
National Institute of General Medical Sciences
NIMH
National Institute of Mental Health
NIMHD
National Institute on Minority Health and Health Disparities
NINDS
National Institute of Neurological Disorders and Stroke
NINR
National Institute of Nursing Research
NLM
National Library of Medicine
OD
NIH Office of the Director
PHS
Public Health Service

Congressional Research Service

20

National Institutes of Health (NIH) Funding: FY1996-FY2023

Author Information

Kavya Sekar

Analyst in Health Policy

Acknowledgments
CRS Research Assistant John Gorman provided assistance for this report.

Disclaimer
This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan
shared staff to congressional committees and Members of Congress. It operates solely at the behest of and
under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other
than public understanding of information that has been provided by CRS to Members of Congress in
connection with CRS’s institutional role. CRS Reports, as a work of the United States Government, are not
subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in
its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or
material from a third party, you may need to obtain the permission of the copyright holder if you wish to
copy or otherwise use copyrighted material.

Congressional Research Service
R43341 · VERSION 45 · UPDATED
21